Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer

BACKGROUND: The previous second-line treatment for HER2-positive metastatic breast cancer were ado-trastuzumab emtansine (T-DM1); however, its activity is decreased in tumors with heterogenous, reduced, or loss of HER2 expression. Trastuzumab deruxtecan (T-DXd) has recently been developed as a novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakajima, Hiromichi, Harano, Kenichi, Nakai, Tokiko, Kusuhara, Shota, Nakao, Takehiro, Funasaka, Chikako, Kondoh, Chihiro, Matsubara, Nobuaki, Naito, Yoichi, Hosono, Ako, Mitsunaga, Shuichi, Ishii, Genichiro, Mukohara, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753267/
https://www.ncbi.nlm.nih.gov/pubmed/34999427
http://dx.doi.org/10.1016/j.breast.2022.01.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753267/
https://www.ncbi.nlm.nih.gov/pubmed/34999427
http://dx.doi.org/10.1016/j.breast.2022.01.002

Ejemplares similares